The Photodynamic Bone Stabilization System: a minimally invasive, percutaneous intramedullary polymeric osteosynthesis for simple and complex long bone fractures.
Paul Vegt, Jeffrey M Muir, Jon E Block
https://pubmed.ncbi.nlm.nih.gov/25540600/Actively Recruiting
Led by Massachusetts General Hospital · Updated on 2026-01-16
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research aims to evaluate the effectiveness of the IlluminOss pelvic implants in patients with pelvic metastatic disease who experience pain, have a risk of pathologic fracture, or present with non-displaced or minimally displaced pathologic fractures of the pelvis. It also includes geriatric patients with pelvic fragility fractures. The goal is to confirm early findings of pain reduction and improved function in these patient groups. The study observes patients who have already agreed to undergo the IlluminOss Pelvic Implant as part of their standard clinical care. This device is a UV light activated polymer implant designed to stabilize pelvic fractures through a minimally invasive approach, adapting to the complex pelvic anatomy without requiring screws in most cases. Patients receive the implant for conditions including metastatic bone disease, multiple myeloma, lymphoma, radiation osteitis, or pelvic fragility fractures in older adults. Participants will complete patient-reported outcome surveys before surgery and at multiple time points after surgery 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years. Researchers will monitor pain levels, functional improvements, and any complications over this 2-year follow-up. This helps to understand the implants impact on pain control, mobility, and overall quality of life.
CONDITIONS
IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
K
Kevin Raskin, MD
S
Shreya Halur, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Massachusetts General Hospital
Lead Sponsor
IlluminOss Medical, Inc.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day procedure with short hospital stay
Participants undergo surgical implantation of the IlluminOss Photodynamic Bone Stabilization System in the pelvis to treat impending or actual pathologic fractures or pelvic fragility fractures.
1 surgical visit
Duration - Up to 2 years after surgery
Participants complete patient-reported outcome surveys and assessments to monitor pain control, function, and recovery after the surgery.
Visits at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years after surgery
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Paul Vegt, Jeffrey M Muir, Jon E Block
https://pubmed.ncbi.nlm.nih.gov/25540600/Carsten Surke, Rahel Meier, Luzian Haug...
https://pubmed.ncbi.nlm.nih.gov/31635518/M Zyskowski, M Crönlein, E Heidt...
https://pubmed.ncbi.nlm.nih.gov/27987018/M Stumpf, T Kraus, W Plötz...
https://pubmed.ncbi.nlm.nih.gov/25783693/Guido W Van Oijen, Paul A Vegt, Tjebbe Hagenaars...
https://pubmed.ncbi.nlm.nih.gov/31950234/Tjebbe Hagenaars, Guido W Van Oijen, W Herbert Roerdink...
https://pubmed.ncbi.nlm.nih.gov/27233355/Thomas Gausepohl, Dietmar Pennig, Steffen Heck...
https://pubmed.ncbi.nlm.nih.gov/28286623/Massachusetts General Hospital
Lead Sponsor
IlluminOss Medical, Inc.
Collaborating Sponsor